<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01709981</url>
  </required_header>
  <id_info>
    <org_study_id>11-02573</org_study_id>
    <nct_id>NCT01709981</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effects of Colchicine in PCI</brief_title>
  <official_title>Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention: Inflammatory Marker Substudy of the Colchicine-PCI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      Peri-procedural inflammation is associated with increased rates of post-procedural myocardial&#xD;
      infarction (MI), which occur in up to 35% of PCI patients and are themselves associated with&#xD;
      increased risk of later MI and death. Statins suppress both inflammatory markers and MI rates&#xD;
      during and after PCI, but ≥ 40% of PCI patients go statin-untreated, due in part to side&#xD;
      effects such as myalgia. Moreover, because their mechanism of action relies on&#xD;
      post-translational effects, statins must be given ≥ 12 to 24 hours prior to PCI, a time frame&#xD;
      that is not always feasible. The investigators propose a novel alternative approach to reduce&#xD;
      inflammation during PCI employing colchicine, an anti-inflammatory medication used frequently&#xD;
      in gout and pericarditis. Colchicine may be particularly applicable to the PCI setting due to&#xD;
      its rapid onset of action and excellent side-effect profile at low doses, as well as its&#xD;
      known mechanisms of action. However, data on colchicine use in patients with coronary disease&#xD;
      is extremely limited, and no studies to date have evaluated the use of colchicine in patients&#xD;
      undergoing PCI. The investigators aim to characterize a potential mechanism of benefit in&#xD;
      patients undergoing PCI by evaluating the effects of colchicine on soluble and leukocyte&#xD;
      surface markers after PCI. The investigators also aim to determine the effects of colchicine&#xD;
      on peri-procedural myonecrosis and MI. Accordingly, the investigators propose a prospective&#xD;
      randomized study to characterize the effect of colchicine on inflammation and peri-procedural&#xD;
      myocnecrosis. Patients referred for possible PCI will be randomized in a double-blinded&#xD;
      fashion to placebo or colchicine (1.2mg 1 to 2 hours before PCI, followed by 0.6mg 1 hour&#xD;
      later). The primary endpoint will be post-procedural interleukin-6 level. Secondary endpoints&#xD;
      will include other relevant soluble and leukocyte-associated inflammatory markers. Sample&#xD;
      size needed is 200 patients undergoing PCI. To adjust for a floor effect, 280 patients&#xD;
      undergoing PCI will be needed. 400 patients will likely be needed to be enrolled to reach 280&#xD;
      PCIs (the remaining will have undergone a diagnostic only procedure). Of note, this is a&#xD;
      substudy of the COLCHICINE-PCI trial (NCT 02594111)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2013</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI</measure>
    <time_frame>30 minutes to 1 hour after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Post-procedural IL-6 Concentration From Baseline to 22-24 hr After PCI</measure>
    <time_frame>baseline to 22-24 hr after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Post-procedural hsCRP Concentration From Baseline to 22-24 hr After PCI</measure>
    <time_frame>baseline to 22-24 hr after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</measure>
    <time_frame>30 minutes to 1 hour after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</measure>
    <time_frame>baseline to 22-24 hr after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be more than 18 years of age and referred for coronary angiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plan for diagnostic-only coronary angiography&#xD;
&#xD;
          -  On colchicine chronically&#xD;
&#xD;
          -  History of intolerance to colchicine&#xD;
&#xD;
          -  Glomerular filtration rate &lt;30mL/minute or on dialysis&#xD;
&#xD;
          -  Active malignancy or infection&#xD;
&#xD;
          -  History of myelodysplasia&#xD;
&#xD;
          -  High-dose statin load &lt;24 hours prior to procedure&#xD;
&#xD;
          -  Use of oral steroids or non-steroidal anti-inflammatory agents other than aspirin&#xD;
             within 72 hours or 3 times the agent's half-life (whichever is longer)&#xD;
&#xD;
          -  Use of strong CYP3A4/P-glycoprotein inhibitors (specifically ritonavir, ketoconazole,&#xD;
             clarithromycin, cyclosporine, diltiazem and verapamil)&#xD;
&#xD;
          -  Unable to consent&#xD;
&#xD;
          -  Participating in a competing study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan VA Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <results_first_submitted>July 23, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NYU Langone Health</investigator_affiliation>
    <investigator_full_name>Binita Shah</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01709981/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01709981/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colchicine</title>
          <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colchicine</title>
          <description>Colchicine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.31" spread="9.29"/>
                    <measurement group_id="B2" value="65.15" spread="10.38"/>
                    <measurement group_id="B3" value="64.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI</title>
        <time_frame>30 minutes to 1 hour after PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI</title>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-161" upper_limit="241"/>
                    <measurement group_id="O2" value="20" lower_limit="-99" upper_limit="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney</non_inferiority_desc>
            <p_value>0.31</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Post-procedural IL-6 Concentration From Baseline to 22-24 hr After PCI</title>
        <time_frame>baseline to 22-24 hr after PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Post-procedural IL-6 Concentration From Baseline to 22-24 hr After PCI</title>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="-6" upper_limit="898"/>
                    <measurement group_id="O2" value="338" lower_limit="27" upper_limit="1264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Post-procedural hsCRP Concentration From Baseline to 22-24 hr After PCI</title>
        <time_frame>baseline to 22-24 hr after PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Post-procedural hsCRP Concentration From Baseline to 22-24 hr After PCI</title>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="-14" upper_limit="80"/>
                    <measurement group_id="O2" value="66" lower_limit="1" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</title>
        <time_frame>30 minutes to 1 hour after PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</title>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="9"/>
                    <measurement group_id="O2" value="0" lower_limit="-5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</title>
        <time_frame>baseline to 22-24 hr after PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Post-procedural IL-1B Concentration From Baseline to 30 Min -1 hr After PCI</title>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0" lower_limit="-9" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days, 6 months, and yearly for 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Colchicine</title>
          <description>1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later&#xD;
Colchicine: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 1-2 hours prior PCI, followed by placebo 1 hour later&#xD;
Placebo: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemodynamic instabiity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Binita Shah</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212-263-6631</phone>
      <email>Binita.Shah@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

